Papers
4
Total Citations
122
H-Index
4
About
Dr. Zhao Ma is a leading surgical oncologist whose research focuses on advancing treatment for esophageal squamous cell carcinoma (ESCC), a particularly aggressive cancer with high prevalence in China. Her most impactful work centers on two key areas: optimizing neoadjuvant immunotherapy strategies and refining minimally invasive surgical techniques. Dr. Ma’s landmark Keystone-001 trial (62 citations) pioneered a novel combination of pembrolizumab with paclitaxel and cisplatin as neoadjuvant therapy for stage III ESCC, with interim results (13 citations) demonstrating promising safety and efficacy—a potential paradigm shift in preoperative management. In surgical innovation, she has systematically compared robot-assisted versus video-assisted McKeown esophagectomy for lymph node dissection around the left recurrent laryngeal nerve (38 citations), establishing robotic approaches as safer and more precise. Her extensive learning curve analysis of 417 patients (9 citations) provides crucial benchmarks for adopting this complex technique. With cumulative citations exceeding 120, Dr. Ma’s work bridges cutting-edge immunotherapy and advanced surgical robotics, directly translating into improved outcomes for patients with locally advanced ESCC. Her contributions are particularly vital given that over 50% of global esophageal cancer cases occur in China.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4